Aptiom® eslicarbazepine acetate tablets Logo.

APTIOM® (eslicarbazepine acetate) is indicated as:

  • Monotherapy in the management of partial-onset seizures in adult patients with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy.
  • Adjunctive therapy in the management of adults, and children above 6 years of age, with partial-onset seizures who are not satisfactorily controlled with conventional therapy.

Download APTIOM® Product Monograph PDF.

CLASTEON® (clodronate disodium) Logo

CLASTEON® (clodronate disodium) is indicated:

  • as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.
  • for the management of hypercalcemia of malignancy.

Download CLASTEON® Product Monograph PDF.

CTP® (citalopram hydrobromide) Logo

CTP® (citalopram hydrobromide) is indicated for the symptomatic relief of depressive illness.

Download CTP® Product Monograph PDF.

CUBICIN® (daptomycin for injection) Logo

CUBICIN® (daptomycin for injection) is indicated for the following infections in adults:

  • Complicated skin and skin structure infections (cSSSI) caused by susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillinresistant strains), Streptococcus pyogenes and Streptococcus agalactiae.
  • Staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided Staphylococcus aureus infective endocarditis (native valve) caused by methicillin-susceptible and methicillin-resistant strains.

Download CUBICIN® Product Monograph PDF.

LATUDA® lurasidone HCI tablets Logo.

LATUDA® (lurasidone HCl) is indicated:

  • for the management of the manifestations of schizophrenia.
  • as monotherapy or as adjunctive therapy with lithium or valproate for the acute management of depressive episodes associated with bipolar I disorder.

Download LATUDA® Product Monograph PDF.

LUNESTA® (eszopiclone) tablets Logo

LUNESTA® (eszopiclone) tablets is indicated for the treatment of insomnia and has been shown to decrease sleep latency and improve sleep maintenance.

Download LUNESTA® Product Monograph PDF.

For more information, please visit:

ORGOVYX® (relugolix tablets, 120 mg) Logo

ORGOVYX® (relugolix tablets, 120 mg) is indicated for the treatment of adult patients with advanced prostate cancer

Download ORGOVYX® Product Monograph PDF.

TROSEC (trospium chloride) Logo

TROSEC® (trospium chloride) is indicated for the treatment of overactive bladder with symptoms of urge or mixed urinary incontinence, urgency, and urinary frequency.

Download TROSEC® Product Monograph PDF.

See full pipeline